Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Outcome of patients with large B-cell lymphoma relapsing after second-line CAR-t: Insights from the descar-t registry

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPierre SesquesLyon CollegeGMGuillaume MansonHôpital PontchaillouGCGuillaume CartronCentre National de la Recherche Scientifique

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals problematic outcomes and limited efficacy of salvage therapies in patients with relapsed large B-cell lymphoma.

Key Points

  • Evaluate outcomes and salvage therapy impact for patients with large B-cell lymphoma relapsing after second-line CAR T-cell therapy.
  • Retrospective analysis of patients using French DESCAR-T registry
  • Categorized salvage treatments into BsAbs monotherapy, combinations, chemotherapy, and other therapies
  • Examined overall survival, overall response rate, and progression-free survival post-relapse
  • 33% of patients experienced disease progression after 2L CAR T-cell therapy
  • Overall response rate to salvage therapy was 39.1%; complete remission in 27.6%
  • Median progression-free survival was 3.4 months, with higher rates related to BsAbs therapies

Cite This Study

Sesques et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e355https://doi.org/10.1182/blood-2025-956
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group2026
  2. 2First-line salvage therapies in relapsed/refractory large B-cell lymphoma after second- or third-line CD19-directed CAR T-cell therapy2025
  3. 3Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models2025
  4. 4Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (<scp>CAR</scp>) T‐cell therapy can be identified before cell administration2024 · 2 citations
  5. 5Association of high-grade biology with marked salvage refractoriness following CD19 CAR T-cell therapy failure in large B-cell lymphoma: A systematic review and meta-analysis.2026